Biomark Capital

Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development to commercial manufacturing with both global and regional regulatory affairs expertise.

Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development to commercial manufacturing with both global and regional regulatory affairs expertise.

BetterDoctor helps validate and deliver accurate provider data to health plans, health systems, and hundreds of other companies via its API — from startups to publicly traded ones. This ultimately helps achieve the mission of helping consumers find the healthcare they need. Today, BetterDoctor's data platform and APIs power 9 health plans, 350 companies, 1,500 developers, helping millions of people find the right doctor each month. Health Plans BetterDoctor uses multi-modal outreach to drive providers to attest their information on BetterDoctor's online portal. API Partners BetterDoctor brings transparency to doctor data. Their real-time platform, master database and API services enable everyone to add doctor data to their systems, websites and applications. Today, BetterDoctor API and data tools power health insurance companies, healthcare startups and doctor search tools. https://betterdoctor.com/developers

Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development to commercial manufacturing with both global and regional regulatory affairs expertise.

i2Dx is developing a multimodal, cloud-based diagnostic platform for the assessment of neurological disorders. The platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized, longitudinal brain record for healthy individuals and patients.

WhiteGlove Health has become a leader in the healthcare industry through providing an extraordinary healthcare experience for members and providing significant cost savings for health plans through reduced insurance claims and reductions in unnecessary utilization. Their comprehensive healthcare strategy is to provide the highest quality care at a predictable cost through highly-skilled nurse practitioners supported by registered nurses in collaboration with physicians, hospitals, other health care providers and carriers. Since 2007, WhiteGlove Health’s highly trained and experienced clinical team comprised of board-certified Nurse Practitioners and Registered Nurses have been making house calls, office calls and providing telephonic support to help members feel better, faster. Their initial focus as a mobile healthcare provider for acute needs and managing chronic conditions has paved the way for the successful introduction of their Value-Based Care division in 2014 which leverages their clinical expertise and ability to deliver provider care to high risk/high cost patients for their Medicare and Medicaid health plan customers. Value-Based Care is conducted at-home or at a Skilled Nursing Facility (SNF) and allows health plans the ability to care for their most challenging patients. Their Solution offers care designed to reduce hospital admissions, re-admissions and prevent unnecessary visits to an emergency room. A WhiteGlove Health Nurse Practitioner has the ability to order or discontinue medications, add home health or durable medical Equipment (as needed) and routinely communicate with the Primary Care Physician on behalf of the patient. The WhiteGlove Health strategy of prompt follow-up and proactive intervention allows us to carefully monitor patients and manage utilization. In June 2014, WhiteGlove Health acquired Glenridge Healthcare Solutions, a leading consulting, technology and professional services firm, founded in 1997 and headquartered in Maryland. Together, their companies are creating more opportunities and efficiencies than they could have achieved independently. Glenridge continues to partner with customers nationwide by providing a seasoned team, advanced data analytic capabilities and state-of-the art technology to their established impressive portfolio.

WaveTec Vision is a small company with a big idea — and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.

HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company’s first product, OxyVu, was developed for the US research market and subsequently received FDA 510(k) approval for medical diagnostic applications where the measurement of microvasculature perfusion can assist physicians with patient care. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market.

MabVax Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative anti-cancer immunotherapies. The company utilizes two primary technology platforms: a series of cancer vaccines developed at Memorial Sloan-Kettering Cancer Center, which are currently in Phase II clinical trials for soft tissue sarcoma and ovarian cancer, and a human antibody discovery platform that leverages immune responses from patients successfully immunized with these vaccines. MabVax’s lead human antibody candidate is in preclinical evaluation for potential treatments targeting colon, pancreatic, and breast cancers. The company has secured significant federal grant funding to support its research and development efforts, underscoring its commitment to advancing novel therapeutic options for cancer patients.

Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.

Flexible Stenting Solutions, Inc. is a privately held medical device company focused on the development and commercialization of flexible stents built on a proprietary design platform. The company has developed a third generation self-expanding stent designed for the harsh loading conditions present in the superficial femoral and popliteal arteries. Their fully connected stent has coupled technology with clinical needs by providing a highly durable and fatigue resistant stent with superior radial stiffness and low chronic outward force. The key to the stent technology is the integration of helically wound struts with helical flexible coils providing a mechanism optimized for vigorous applications. The key to the delivery technology is simplicity, ease of use and placement. Flexible Stenting Solutions received CE Mark authorization for both its FlexStent® Femoropopliteal and Biliary Self Expanding (SE) Stent Systems in January 2009. The company received 510(k) clearance for its FlexStent® Biliary Self Expanding Stent System in September 2009. This stent will provide a significant benefit to patients requiring palliation of malignant biliary strictures by relieving symptoms caused by biliary obstruction.

MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

Spectral Image is a privately held, early stage medical device company focused on the development of imaging technology for biomedical use. The company is currently in stealth-mode and not disclosing the finer details of its technology until it secures necessary intellectual property rights. Spectral Image will initiate a pilot study of its technology at one of the nation's premier medical facilities in 2008. The company, founded in 2007, is headquartered in Florida, and GBP Capital is the company's sole investor.